Management of osteoporosis final

Osteoporosis Definition ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

Osteoporosis ,[object Object],[object Object],[object Object],[object Object],05/01/10

Diagnosis: x-ray -No ,[object Object],[object Object],[object Object],05/01/10

Bone Mineral Density ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GOLD STANDARD 05/01/10

WHO Classification Normal : BMD within 1 to -1 SD Osteopenia :BMD -1 - 2.5 SD Osteoporosis :BMD -2.5 SD or more 05/01/10

MANAGEMENT ,[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

CALCIUM AND VITAMIN D ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

Updated National Osteoporosis Foundation (NOF) guidelines 2008 ,[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

Drugs available and on horizons ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

ESTROGEN ,[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

HT ,[object Object],[object Object],[object Object],[object Object],05/01/10

SERMS- RALOXIFENE (EVISTA®) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

SERM- Bazedoxifene ,[object Object],[object Object],[object Object],[object Object],05/01/10

Selective Estrogen Receptor-ß Agonist, MF-101 ( 22 chinese herbal medicines) ,[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

TSEC & SERMS ,[object Object],[object Object],05/01/10

BISPHOSPHONATES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

Alendronate (Bishphonate) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

RISEDRONATE (ACTONEL®) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

RISEDRONATE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

CALCITONIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

CALCITONIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

CALCITONIN ,[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

ANABOLIC AGENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

PTH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

PTH (Forteo) Neer et al. (2001) NEJM 344(19), 1434-1441 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

PTH (Forteo) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

New Drug Denosumab ,[object Object],05/01/10

Dose of Denosumab ,[object Object],05/01/10

ORTHOSIS ,[object Object],[object Object],[object Object],[object Object],05/01/10 dr.maninder AICOG2009 Improved back extensor strength correlate with decreased kyphosis and diminished vertebral fracture risk. Hip protectors don’t reduce incidence of hip fractures Van Schoor NM, Smit JH, Twisk JWR, et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA . 2003;289(15):1957–1962

FALL PREVENTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10 dr.maninder AICOG2009

To Summarise”Drugs for prevention&treatment” ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10 dr.maninder AICOG2009

Lower Higher -2.5 BMD (T-score) Bisphosphonates Osteoporosis Therapy Algorithm Postmenopausal Women 05/01/10 Raloxifene PTH Calcitonin HRT HRT During Hot Flashes Post Vasomotor Symptoms Pre fracture Post Fracture Risk of Fracture AGE At Risk/Osteopenia Osteoporosis Severe Osteoporosis STAGE

OSTEOPOROSIS HIP FRACTURES 05/01/10

OSTEOPOROSIS HIP FRACTURES ,[object Object],[object Object],[object Object],05/01/10

OSTEOPOROSIS SPINE FRACTURES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],05/01/10

Final Word ,[object Object],[object Object],05/01/10

Final Message ,[object Object],[object Object],[object Object],05/01/10

ACKNOWLEDGEMENT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dr.Maninder Ahuja Chairperson Geriatric Gynecology Committee FOGSI 05/01/10

Management of osteoporosis final

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (20)

Similaire à Management of osteoporosis final

Similaire à Management of osteoporosis final (20)

Plus de Shambhu N

Plus de Shambhu N (17)

Dernier

Dernier (20)

Management of osteoporosis final

Notes de l'éditeur